Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jbc.2021.100375 http://scihub22266oqcxt.onion/10.1016/j.jbc.2021.100375 33548227!7857991!33548227     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Biol+Chem 2021 ; 296 (ä): 100375 Nephropedia Template TP {{tp|p=33548227|t=2021. How glycobiology can help us treat and beat the COVID-19 pandemic |pdf=|usr=}}{{33548227}} gab.com Text How glycobiology can help us treat and beat the COVID-19 pandemic JO: J Biol Chem http://www.kidney.de/pget.php?&tw=1&pmid=33548227 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged during the last months of 2019, spreading throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review focuses on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next-generation drugs suggested here, biotechnological engineering of new probes to block the SARS-CoV-2 infection might be based on the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins, and glycosidases related to this pathology. Twit Text FOAVip How glycobiology can help us treat and beat the COVID-19 pandemic ????J Biol Chem http://www.kidney.de/pget.php?&tw=1&pmid=33548227 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33548227 #FOAvip English Wikipedia <ref>{{Cite pmid|33548227}}</ref> How glycobiology can help us treat and beat the COVID-19 pandemic #MMPMID33548227 Lardone RD; Garay YC; Parodi P; de la Fuente S; Angeloni G; Bravo EO; Schmider AK; Irazoqui FJ J Biol Chem 2021[Jan]; 296 (ä): 100375 PMID33548227show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged during the last months of 2019, spreading throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review focuses on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next-generation drugs suggested here, biotechnological engineering of new probes to block the SARS-CoV-2 infection might be based on the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins, and glycosidases related to this pathology. |*Drug Repositioning[MESH] |Antibodies, Neutralizing/therapeutic use[MESH] |Antiviral Agents/chemistry/*therapeutic use[MESH] |COVID-19/epidemiology/immunology/*prevention & control/virology[MESH] |Drug Design[MESH] |Drug Discovery[MESH] |Gene Expression[MESH] |Glycomics/methods[MESH] |Glycosaminoglycans/chemistry/immunology/metabolism[MESH] |Glycoside Hydrolase Inhibitors/*therapeutic use[MESH] |Glycosyltransferases/*antagonists & inhibitors/chemistry/genetics/immunology[MESH] |Host-Pathogen Interactions/drug effects/genetics/immunology[MESH] |Humans[MESH] |Lectins/chemistry/immunology/metabolism[MESH] |Polysaccharides/chemistry/immunology/metabolism[MESH] |SARS-CoV-2/chemistry/drug effects/genetics/immunology[MESH] |Signal Transduction[MESH]How glycobiology can help us treat and beat the COVID-19 pandemic (epmc).pdf DeepDyve Pubget Overpricing